Search results

20 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
In development Remove In development filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Quality standards Remove Quality standards filter

Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

In development [GID-HST10052] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Sebelipase alfa for treating Wolman disease [ID3995]

In development [GID-HST10047] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Human alpha1-proteinase inhibitor for treating emphysema ID856

In development [GID-HST10017] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

In development [GID-HST10033] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642

In development [GID-HST10044] Expected publication date: 25 January 2023

Type

Highly specialised technologies guidance

Status

In development
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Onasemnogene abeparvovec for treating spinal muscular atrophy (review of HST15) [ID4051]

In development [GID-HST10053] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]

In development [GID-HST10034] Expected publication date: 20 July 2022

Type

Highly specialised technologies guidance

Status

In development
Skin abscess: antimicrobial prescribing

In development [GID-NG10163] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Conjunctivitis: antimicrobial prescribing

In development [GID-NG10166] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Blepharitis: antimicrobial prescribing

In development [GID-NG10168] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Stye: antimicrobial prescribing

In development [GID-NG10167] Expected publication date: TBC

Type

Antimicrobial prescribing guideline

Status

In development
Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

In development [GID-HST10050] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

In development [GID-HST10037] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818

In development [GID-HST10040] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

In development [GID-HST10038] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development

Filter (5 in use)

Area of interest

Type 1 selected

Status 1 selected

Last updated

Guidance programme 3 selected

20 results

Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]

Sebelipase alfa for treating Wolman disease [ID3995]

Velmanase alfa for treating alpha-mannosidosis [ID800]

Human alpha1-proteinase inhibitor for treating emphysema ID856

Afamelanotide for treating erythropoietic protoporphyria [ID927]

Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642

Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

Onasemnogene abeparvovec for treating spinal muscular atrophy (review of HST15) [ID4051]

Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]

Skin abscess: antimicrobial prescribing

Conjunctivitis: antimicrobial prescribing

Blepharitis: antimicrobial prescribing

Stye: antimicrobial prescribing

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

Arimoclomol for treating Niemann-Pick disease Type C [ID1312]

Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818

Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]